Nexstim Oyj (STU:5NX)

Half Year 2025 Nexstim Oyj Earnings Call Transcript

Aug 15, 2025 / 12:00 PM GMT

Release Date Price: €14.65 (+0.69%)

Transcript

Key Points

Positve

Nexstim Oyj (OHEL:NXTMH) reported over 40% revenue growth in the first half of 2025, aligning with their strategic objective of profitable revenue growth.
The company achieved a positive EBITDA of 0.2 million euros, marking the second consecutive half-year of positive EBITDA.
Nexstim Oyj (OHEL:NXTMH) has a strong partnership with Brainlab AG, which is expected to drive growth in the diagnostics business.
The company has signed an exclusivity agreement with Synaptica Therapeutics for research in Alzheimer's treatment, indicating potential future commercial opportunities.
The launch of the new NBS 6 product is anticipated to enhance both diagnostic and therapeutic capabilities, supporting long-term growth and customer satisfaction.

Negative

Despite positive EBITDA, the operating results and results for the period were still negative, indicating ongoing financial challenges.
Therapy business net sales decreased by 8.4%, primarily due to lower system sales compared to the previous period.
The company is still awaiting FDA approvals for chronic pain treatment, which limits their market potential in the United States.
There is a dependency on regulatory approvals for the new NBS 6 system, which could delay market entry if not obtained timely.
The company's business is traditionally cyclical, which can lead to variability in financial performance and potential unpredictability in revenue streams.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

NXTMH.HE - Nexstim Oyj
Half Year 2025 Nexstim Oyj Earnings Call
Aug 15, 2025 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome, everyone. My name is Miko Carvin and I'm the CEO of Nextten.

And, I will be joined in this webinar with, our CFO Jonas Lolatti.

And we will, we are happy to go through our first half, 2025 financial results in this webinar.

And we will begin this webinar by, I will be going through a bit about the general story and next in business, continued by, of course, the H1, as a summary, and then Jonas will be going through some of the financials in more detail. And then at the end of the The webinar, I'll come back with some of our 2025 key strategic objectives and and finalize with some information on our new NBS 6 product.

So we can go forward with starting off a bit about our strategy, and we started

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.